etidronate has been researched along with Vascular Calcification in 19 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 9.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 6.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks)." | 5.27 | Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum. ( Bartstra, JW; de Jong, PA; de Vries, JJ; den Harder, AM; Imhof, SM; Kranenburg, G; Lagerweij, SJ; Lam, MG; Luurtsema, G; Mali, WP; Ossewaarde-van Norel, J; Risseeuw, S; Slart, RHJA; Spiering, W; van Leeuwen, R; Verhaar, HJ; Visseren, FLJ, 2018) |
| " In vivo, the rats were treated with vitamin D3 to induce vascular calcification and then intravenously administered FYB-931 or etidronate thrice weekly for 2 weeks." | 4.02 | Assessment of calciprotein particle formation by AUC of the absorbance change: effect of FYB-931, a novel bisphosphonate compound. ( Ashizawa, N; Ishida, K; Iwanaga, T; Kobashi, S; Kurita, N; Morikane, S, 2021) |
| "Etidronate treatment halts systemic arterial calcification in PXE." | 2.94 | Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum. ( Bartstra, JW; de Jong, PA; den Harder, AM; Isgum, I; Kranenburg, G; Mali, WPTM; Spiering, W; Wijsman, A; Wolf, B; Wolterink, JM, 2020) |
| "Pseudoxanthoma elasticum is a prototype of heritable ectopic mineralization disorders, with phenotypic overlap with generalized arterial calcification of infancy and arterial calcification due to CD73 deficiency." | 2.55 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. ( Li, Q; Terry, SF; Uitto, J; van de Wetering, K; Váradi, A, 2017) |
| "Vascular calcification is an active process in which vascular smooth muscle cells (VSMCs) adopt an osteoblastic phenotype and deposit hydroxyapatite crystals; apoptosis of VSMCs also promotes this deposition." | 2.50 | The molecular biology and pathophysiology of vascular calcification. ( DiNicolantonio, JJ; McCarty, MF, 2014) |
| " Considering low bioavailability of bisphosphonates when administered orally, subsequent studies tested the mice with subcutaneous injections of etidronate." | 1.43 | Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy. ( Kingman, J; Levine, MA; Li, Q; Sundberg, JP; Uitto, J, 2016) |
| "Treatment with etidronate had no effect on bone parameters in the WT mice; however, the Enpp1-/- mice displayed an increased structural model index (SMI; P<0." | 1.42 | Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy. ( Huesa, C; MacRae, VE; Millán, JL; Staines, KA, 2015) |
| "We report bisphosphonate-related enamel hypoplasia as a rare side effect in a child with idiopathic arterial calcification of infancy." | 1.39 | Bisphosphonate-related enamel hypoplasia in a child with idiopathic arterial calcification of infancy. ( Isomatsu, Y; Iwai, T; Iwamoto, M; Tohnai, I, 2013) |
| "Atherosclerotic plaque formation and vascular calcinosis were modeled in a subchronic experiment." | 1.38 | Biochemical indicators of atherogenic and protective activity of xydiphone in experimental animals. ( Dreval, AA; Ilyushina, IA; Murashov, AN; Pimenov, MS; Sukhorukov, VS; Yur'eva, EA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Bartstra, JW | 2 |
| de Jong, PA | 2 |
| Kranenburg, G | 2 |
| Wolterink, JM | 1 |
| Isgum, I | 1 |
| Wijsman, A | 1 |
| Wolf, B | 1 |
| den Harder, AM | 2 |
| Mali, WPTM | 1 |
| Spiering, W | 2 |
| Stumpf, MJ | 1 |
| Schaefer, CA | 1 |
| Schahab, N | 1 |
| Ishida, K | 2 |
| Ashizawa, N | 2 |
| Morikane, S | 1 |
| Kurita, N | 2 |
| Kobashi, S | 2 |
| Iwanaga, T | 2 |
| Uitto, J | 4 |
| Li, Q | 4 |
| van de Wetering, K | 1 |
| Váradi, A | 1 |
| Terry, SF | 2 |
| Lagerweij, SJ | 1 |
| Lam, MG | 1 |
| Ossewaarde-van Norel, J | 1 |
| Risseeuw, S | 1 |
| van Leeuwen, R | 1 |
| Imhof, SM | 1 |
| Verhaar, HJ | 1 |
| de Vries, JJ | 1 |
| Slart, RHJA | 1 |
| Luurtsema, G | 1 |
| Visseren, FLJ | 1 |
| Mali, WP | 1 |
| Matsumoto, K | 1 |
| Shigematsu, T | 1 |
| McCarty, MF | 1 |
| DiNicolantonio, JJ | 1 |
| Apschner, A | 1 |
| Huitema, LF | 1 |
| Ponsioen, B | 1 |
| Peterson-Maduro, J | 1 |
| Schulte-Merker, S | 1 |
| Sundberg, JP | 2 |
| Levine, MA | 2 |
| Moore, SN | 1 |
| Tanner, SB | 1 |
| Schoenecker, JG | 1 |
| Huesa, C | 1 |
| Staines, KA | 1 |
| Millán, JL | 2 |
| MacRae, VE | 1 |
| Kingman, J | 1 |
| Edouard, T | 1 |
| Chabot, G | 1 |
| Miro, J | 1 |
| Buhas, DC | 1 |
| Nitschke, Y | 1 |
| Lapierre, C | 1 |
| Rutsch, F | 1 |
| Alos, N | 1 |
| Iglesias-Platas, I | 1 |
| del Río, R | 1 |
| Rodríguez, XF | 1 |
| Rodríguez, X | 1 |
| Pedrini, M | 1 |
| Rebollo-Polo, M | 1 |
| Iriondo, M | 1 |
| Iwai, T | 1 |
| Isomatsu, Y | 1 |
| Iwamoto, M | 1 |
| Tohnai, I | 1 |
| Mori, H | 1 |
| Okada, Y | 1 |
| Tanaka, Y | 1 |
| Hashimoto, O | 1 |
| Otero, JE | 1 |
| Gottesman, GS | 1 |
| McAlister, WH | 1 |
| Mumm, S | 1 |
| Madson, KL | 1 |
| Kiffer-Moreira, T | 1 |
| Sheen, C | 1 |
| Ericson, KL | 1 |
| Whyte, MP | 1 |
| Yur'eva, EA | 1 |
| Sukhorukov, VS | 1 |
| Murashov, AN | 1 |
| Pimenov, MS | 1 |
| Ilyushina, IA | 1 |
| Dreval, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)[NCT04660461] | Phase 4 | 20 participants (Anticipated) | Interventional | 2020-02-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for etidronate and Vascular Calcification
| Article | Year |
|---|---|
Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Animals; Biopsy, Needle; Clinical Trials as Topic; Congresses | 2017 |
The molecular biology and pathophysiology of vascular calcification.
Topics: Antioxidants; Biomarkers; Bone Density Conservation Agents; Etidronic Acid; Humans; Magnesium; Muscl | 2014 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Diphosphonates; Etidron | 2012 |
2 trials available for etidronate and Vascular Calcification
| Article | Year |
|---|---|
Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum.
Topics: Aged; Arteries; Etidronic Acid; Female; Humans; Male; Middle Aged; Pseudoxanthoma Elasticum; Single- | 2020 |
Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Calcium; Drug Monitoring; Etidronic Acid; Fema | 2018 |
14 other studies available for etidronate and Vascular Calcification
| Article | Year |
|---|---|
From osteoporosis to pseudoxanthoma elasticum - etidronate in a vascular disease.
Topics: Etidronic Acid; Humans; Osteoporosis; Pseudoxanthoma Elasticum; Vascular Calcification; Vascular Dis | 2020 |
Assessment of calciprotein particle formation by AUC of the absorbance change: effect of FYB-931, a novel bisphosphonate compound.
Topics: Animals; Area Under Curve; Calcium Phosphates; Calcium-Regulating Hormones and Agents; Colloids; Dip | 2021 |
Vascular Mineralization in Pseudoxanthoma Elasticum: Etidronate to the Rescue?
Topics: Etidronic Acid; Humans; Pseudoxanthoma Elasticum; Vascular Calcification | 2018 |
Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats.
Topics: Animals; Aorta; Biomarkers; Bone Resorption; Cells, Cultured; Cholecalciferol; Diphosphonates; Etidr | 2019 |
Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE).
Topics: Animals; Biomarkers; Calcinosis; Calcium; Choristoma; Etidronic Acid; Fibroblast Growth Factor-23; H | 2014 |
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Drug Eval | 2015 |
Bisphosphonates: from softening water to treating PXE.
Topics: Alendronate; Animals; ATP-Binding Cassette Transporters; Bone Density Conservation Agents; Etidronic | 2015 |
Effects of etidronate on the Enpp1⁻/⁻ mouse model of generalized arterial calcification of infancy.
Topics: Animals; Aorta; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Disease | 2015 |
Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
Topics: Animals; Animals, Newborn; Biopsy, Needle; Bone and Bones; Choristoma; Diphosphonates; Disease Model | 2016 |
Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy.
Topics: Absorptiometry, Photon; Angiography; Bone Density Conservation Agents; Diagnosis, Differential; DNA; | 2011 |
Two new cases of idiopathic arterial calcification in the newborn: watch out for lineal calcifications in plain radiographs.
Topics: Bone Density Conservation Agents; Etidronic Acid; Fatal Outcome; Humans; Infant, Newborn; Lower Extr | 2012 |
Bisphosphonate-related enamel hypoplasia in a child with idiopathic arterial calcification of infancy.
Topics: Bone Density Conservation Agents; Child; Dental Enamel Hypoplasia; Diphosphonates; Etidronic Acid; F | 2013 |
Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy.
Topics: Adult; Bone Diseases; Child; Child, Preschool; Etidronic Acid; Female; Humans; Infant; Infant, Newbo | 2013 |
Biochemical indicators of atherogenic and protective activity of xydiphone in experimental animals.
Topics: Alkaline Phosphatase; Animals; Atherosclerosis; Biomarkers; Cholesterol, LDL; Creatine Kinase; Creat | 2012 |